<p>总体而言，美国股市在周三想要参与 <strong>Tilray Brands</strong>（TLRY 5.00%）。这家加拿大大麻公司的股票当天上涨了 5%，尽管这主要是由于外部新闻，而非任何内部发展。凭借这一涨幅，Tilray 轻松超越了当天上涨幅度相对较小的 <strong>标准普尔 500 指数</strong>，后者仅上涨了 0.4%。</p>
<h2>可能的替代方案</h2>
<p>像 Tilray 这样的 marijuana 公司股票价格往往在与该药物相关的医学测试结果积极或在美国朝着事实上的合法化迈进时波动。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzgyNDkvcGVyc29uLWluLWxhYi1nZWFyLXdvcmtpbmctd2l0aC1tYXJpanVhbmEtcGxhbnRzLmpwZyZ3PTcwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzgyNDkvcGVyc29uLWluLWxhYi1nZWFyLXdvcmtpbmctd2l0aC1tYXJpanVhbmEtcGxhbnRzLmpwZyZ3PTcwMA"/></p>
<p>图片来源：Getty Images。</p>
<p>周三，前一类新闻为将大麻视为医学有用产品提供了支持。由乔治亚州和科罗拉多州大学的研究人员组成的团队发现，法律宽松的州在处方阿片类药物方面显示出 “显著” 的减少。</p>
<p>尽管阿片类药物在正确和谨慎使用时是安全的，但许多药物也非常上瘾，因此具有显著的滥用潜力。</p>
<p>研究人员在分析 2007 年至 2020 年间数百万美国人的处方索赔的研究中发现，患者被开处方阿片类药物的比例平均下降了 16%。一些未被识别的州甚至达到了 22%。</p>
<h2>合法化仍然是最佳前进方向</h2>
<p>大麻在某些类型的治疗中被证明是有益的程度越高，政治家们就越有理由改革禁止大麻的联邦法律。这才是真正能够改变 Tilray 及其众多挣扎中的大麻行业同行命运的因素。美国各州当前零散的合法化体系并不利于该行业公司的发展。</p>

TLRY

<p>Tilray Brands (TLRY) 的股价上涨了 5%，超过了标准普尔 500 指数 0.4% 的涨幅，这一增长主要受到外部新闻的推动，而非公司内部的发展。乔治亚州和科罗拉多州大学的研究表明，实施宽松大麻法律的州在阿片类药物处方方面平均减少了 16%，这暗示了大麻的潜在医疗益处。这可能有助于支持联邦合法化的论点，而这对 Tilray 和大麻行业的增长至关重要</p>

<p>As a whole, the U.S. stock market wanted to partake of <strong>Tilray Brands</strong>(TLRY 5.00%) on Wednesday. The Canadian cannabis company's shares enjoyed a 5% lift on the day, although this was due to external news rather than any proprietary development. With that gain, Tilray easily beat the <strong>S&amp;P 500</strong> index, which rose by a relatively light 0.4% that day.</p>
<div class="lb-trans"><p>总体而言，美国股市在周三想要参与 <strong>Tilray Brands</strong>（TLRY 5.00%）。这家加拿大大麻公司的股票当天上涨了 5%，尽管这主要是由于外部新闻，而非任何内部发展。凭借这一涨幅，Tilray 轻松超越了当天上涨幅度相对较小的 <strong>标准普尔 500 指数</strong>，后者仅上涨了 0.4%。</p>
</div><h2>A possible alternative</h2>
<div class="lb-trans"><h2>可能的替代方案</h2>
</div><p>The stock prices of marijuana companies like Tilray tend to move when there are positive results from medical testing related to the drug or some kind of move toward de facto legalization in this country.</p>
<div class="lb-trans"><p>像 Tilray 这样的 marijuana 公司股票价格往往在与该药物相关的医学测试结果积极或在美国朝着事实上的合法化迈进时波动。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzgyNDkvcGVyc29uLWluLWxhYi1nZWFyLXdvcmtpbmctd2l0aC1tYXJpanVhbmEtcGxhbnRzLmpwZyZ3PTcwMA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F838249%2Fperson-in-lab-gear-working-with-marijuana-plants.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><p>On Wednesday, a news item in the former category provided support for the treatment of weed as a medically useful product. A team comprised of researchers from the universities of Georgia and Colorado found that states with lenient pot laws have been demonstrating &#34;significant&#34; reductions in the prescribing of opioids.</p>
<div class="lb-trans"><p>周三，前一类新闻为将大麻视为医学有用产品提供了支持。由乔治亚州和科罗拉多州大学的研究人员组成的团队发现，法律宽松的州在处方阿片类药物方面显示出 “显著” 的减少。</p>
</div><p>Although opioids are safe when used properly and carefully, many are also very addictive and thus have notable potential for abuse.</p>
<div class="lb-trans"><p>尽管阿片类药物在正确和谨慎使用时是安全的，但许多药物也非常上瘾，因此具有显著的滥用潜力。</p>
</div><p>The researchers found, in a study analyzing millions of prescription claims from 2007 to 2020 for millions of Americans, that the rate of patients being prescribed opioids declined by 16% on average. Some states it did not identify reached 22%.</p>
<div class="lb-trans"><p>研究人员在分析 2007 年至 2020 年间数百万美国人的处方索赔的研究中发现，患者被开处方阿片类药物的比例平均下降了 16%。一些未被识别的州甚至达到了 22%。</p>
</div><h2>Legalization still the best way forward</h2>
<div class="lb-trans"><h2>合法化仍然是最佳前进方向</h2>
</div><p>The more that cannabis can be shown to be beneficial in certain types of treatment, the more justification politicians have for reforming federal law prohibiting it. And that's what's really going to turn around the fortunes of Tilray and its many struggling weed industry peers. The current patchy system of legalization in U.S. states is not conducive to the growth of the sector's companies.</p>
<div class="lb-trans"><p>大麻在某些类型的治疗中被证明是有益的程度越高，政治家们就越有理由改革禁止大麻的联邦法律。这才是真正能够改变 Tilray 及其众多挣扎中的大麻行业同行命运的因素。美国各州当前零散的合法化体系并不利于该行业公司的发展。</p>
</div>

为什么投资者今天对 Tilray Brands 的股票感到兴奋